Dr. Tracy J. Eicher, M.D.
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- University of Kansas School of Med (Kc/Wich/Sal) (2001)
- Years since graduation
- 25
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 90
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2001Medical school: University of Kansas School of Med (Kc/Wich/Sal)
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
OH license 35088726 · KY license TP648
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Miami Valley Hospital Dayton, OH
Medical groups
- Premier Health Specialists Inc (580 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 90
- Services billed
- 5,874
- Patients’ average age
- 68
| Service | Times | Patients |
|---|---|---|
| Injection, ocrelizumab, 1 mg | 6,600 | 11 |
| Injection, onabotulinumtoxina, 1 unit | 6,350 | 13 |
| Established patient office or other outpatient visit, 30-39 minutes | 34 | 32 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 33 | 19 |
| Administration of chemotherapy into vein, each additional hour | 26 | 13 |
| Established patient office or other outpatient visit, 20-29 minutes | 24 | 22 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 18 | 14 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 17 | 17 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 15 | 14 |
| Administration of chemotherapy into vein, 1 hour or less | 14 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gabapentin Other prescribers in Dayton, OH | 24 |
| Baclofen Other prescribers in Dayton, OH | 18 |
| Kesimpta Pen (ofatumumab) | 14 |
| Oxcarbazepine Other prescribers in Dayton, OH | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 35 payments worth $36,912 in total to this clinician.
| Alexion Pharmaceuticals, Inc. | $26,805 |
|---|---|
| Merck Healthcare Kgaa | $3,187 |
| Merck Kgaa | $3,000 |
| EMD Serono, Inc. | $2,516 |
| Tg Therapeutics, Inc. | $1,350 |
| AbbVie Inc. | $53.76 |
| Compensation for services other than consulting (speaking, faculty) | $24,190 |
|---|---|
| Consulting Fee | $9,937 |
| Travel and Lodging | $1,996 |
| Food and Beverage | $673 |
| Education | $116 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Alexion Pharmaceuticals, Inc. Apr 10, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $5,900 |
| Alexion Pharmaceuticals, Inc. Jun 12, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $4,720 |
| Alexion Pharmaceuticals, Inc. Oct 16, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $4,720 |
| Alexion Pharmaceuticals, Inc. Feb 6, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $3,540 |
| Alexion Pharmaceuticals, Inc. Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $3,540 |
| Merck Kgaa Dec 29, 2025 | Consulting FeeCompany’s descriptionConsulting Services (Fee For Service) | $3,000 |
| EMD Serono, Inc. Aug 25, 2025 | Consulting Fee Mavenclad · Neurology Company’s descriptionAdvisory Board Participation (Fee For Service) | $2,400 |
| Alexion Pharmaceuticals, Inc. May 1, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $1,770 |
| Merck Healthcare Kgaa Nov 5, 2025 | Consulting FeeCompany’s descriptionAdvisory Board Participation (Fee For Service) | $1,387 |
| Tg Therapeutics, Inc. Jul 29, 2025 | Consulting Fee BRIUMVI · Immunology | $1,350 |
All 25 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Merck Kgaa Dec 29, 2025 | Consulting FeeCompany’s descriptionConsulting Services (Fee For Service) | $3,000 |
| Merck Healthcare Kgaa Nov 17, 2025 | Consulting FeeCompany’s descriptionAdvisory Board Participation (Fee For Service) | $900 |
| Merck Healthcare Kgaa Nov 17, 2025 | Consulting FeeCompany’s descriptionAdvisory Board Participation (Fee For Service) | $900 |
| Merck Healthcare Kgaa Nov 5, 2025 | Consulting FeeCompany’s descriptionAdvisory Board Participation (Fee For Service) | $1,387 |
| Alexion Pharmaceuticals, Inc. Oct 16, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $4,720 |
| Alexion Pharmaceuticals, Inc. Oct 11, 2025 | Travel and Lodging travel to Dayton, OH | $210 |
| Alexion Pharmaceuticals, Inc. Oct 11, 2025 | Travel and Lodging travel to Louisville, KY | $187 |
| Alexion Pharmaceuticals, Inc. Oct 11, 2025 | Travel and Lodging travel to Louisville, KY | $8.00 |
| Alexion Pharmaceuticals, Inc. Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $3,540 |
| Alexion Pharmaceuticals, Inc. Sep 26, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Dayton, OH | $101 |
| EMD Serono, Inc. Sep 8, 2025 | Education in-kind Company’s descriptionReprints | $57.98 |
| EMD Serono, Inc. Sep 8, 2025 | Education in-kind Company’s descriptionReprints | $57.98 |
| EMD Serono, Inc. Aug 25, 2025 | Consulting Fee Mavenclad · Neurology Company’s descriptionAdvisory Board Participation (Fee For Service) | $2,400 |
| Tg Therapeutics, Inc. Jul 29, 2025 | Consulting Fee BRIUMVI · Immunology | $1,350 |
| Alexion Pharmaceuticals, Inc. Jun 12, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $4,720 |
| Alexion Pharmaceuticals, Inc. May 5, 2025 | Travel and Lodging travel to Detroit, MI | $311 |
| Alexion Pharmaceuticals, Inc. May 5, 2025 | Travel and Lodging travel to Detroit, MI | $20.00 |
| Alexion Pharmaceuticals, Inc. May 1, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $1,770 |
| Alexion Pharmaceuticals, Inc. Apr 10, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $5,900 |
| Alexion Pharmaceuticals, Inc. Mar 21, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Boston, MA · in-kind Company’s descriptionSpeaker Expenses | $722 |
| Alexion Pharmaceuticals, Inc. Mar 21, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Boston, MA · in-kind Company’s descriptionSpeaker Expenses | $255 |
| Alexion Pharmaceuticals, Inc. Mar 21, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Dayton, OH | $44.00 |
| Alexion Pharmaceuticals, Inc. Mar 21, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Boston, MA · in-kind Company’s descriptionSpeaker Expenses | $29.99 |
| Alexion Pharmaceuticals, Inc. Feb 6, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $3,540 |
| Alexion Pharmaceuticals, Inc. Jan 15, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Columbus, OH | $109 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $53,419 in research payments for these studies, mostly to the institutions running them.
- A phase iii study to evaluate the efficacy and safety of fenebrutinib in adults with progressive ms
Genentech, Inc. - Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment
Roche Products Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.